Cardioselective beta-adrenoreceptor blockade with betaxolol in cardiovascular therapy
Abstract
Beta-adrenoreceptor blockers are widely used in the treatment of various cardiovascular diseases. The review discusses the benefits of a highly selective beta-adrenoblocker betaxolol in patients with coronary heart disease, arterial hypertension, cardiac arrhythmias, and chronic heart failure. Possible adverse effects are also discussed, including metabolic, bronchial, and lactation-related ones.
References
1. The CAPRICON investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction. The CAPRICON randomised trial. Lancet 2001; 357: 1385-90.
2. CIBIS-II investigators and committees. The cardiac insufficiency bisoprolol Study II (CIBIS-II): a randomised trail. Lancet 1999; 353: 9-13.
3. MERIT-HF study group. Effect of metaprolol CR/XL in chronic heart failure. Metaprolol CR/XL randomised intervention trail in congestive heart failure. Lancet 1999; 353: 2001-7.
4. Packer M, Coats AJS, Fowler MB, et al. for the carvedilol prospec¬tive randomised cumulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 1651-8.
5. Lopez-Sendon J, Swedberg K, McMurray J, et al. Exepert consensus document on p—adrenergic receptor blockers. The Task Force on beta-blockers of the European Society of Cardiology. Euro Heart J 2004; 25: 1341-62.
6. Ludden TM, Boyle DA, Gieseker D, et al. Absolute bioavailability and dose proportionality of betaxolol in normal healthy subjects. J Pharm Sci 1988; 77(9): 779-83.
7. Lipworth BJ, Irvine NA, McDevitt DG. The effects of time and dose on the relative beta 1- and beta 2-adrenoceptor antagonism of betaxolol and atenolol. Br J Clin Pharmacol 1991; 31(2): 154-9.
8. Lipworth BJ, Irvine NA, McDevitt DG. The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol. Eur J Clin Pharmacol 1991; 40(5): 467-71.
9. Zateyshchikov DA, Minushkina LO, Brovkin AN, et al. Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol 2007; 21(4): 437-43.
10. Hollenbeck M, Plum J, Heering P, et al. Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension. J Hypertens 1991; 9(9): 819-24.
11. Os JS, Brummelen P, Woittiez AJ. Betaxolol in obese hypertensive patients. Long-term effects on blood pressure and serum lipids. Neth J Med 1992; 40(5-6): 227-31.
12. Williams RL, Goyle KK, Herman TS, et al. Dose-dependent effects of betaxolol in hypertension: a double-blind, multicenter study. J Clin Pharmacol 1992; 32(4): 360-7.
13. Soucek M, Julinek J, Rihacek I, Stejfa M. Betaxolol hydrochloride in the treatment of mild and medium hypertension--long-term effects. Vnitr Lek 1995; 41(9): 605-8.
14. Keltai M, Matos L, Ofner P. Effect of betaxolol on blood pressure and heart rate in mild to moderate hypertension. Orv Hetil 1997; 138(42): 2661-4.
15. Соболева Г.Н., Карпов Ю.А., Рогоза А.Н., Кухарчук В. В. Влияние бета-блокатора пролонгированного действия бетаксолола на суточный профиль артериального давления у больных гипертонической болезнью. Кардиология 1997; 5: 26-30.
16. Soucek M, Rihacek I, Frana P. A comparison of the trough-to-peak ratio of cardio-selective beta-blockers in patients with newly diagnosed hypertension. Blood Press Monit 2006; 11(6): 337-42.
17. Rihacek I, Soucek M, Frana P. The smoothness index of betaxolol hydrochloride in patients with newly diagnosed hypertension. Vnitr Lek 2007; 53(1): 25-30.
18. Быстрова М.М., Бритов А.Н., Горбунов В.М. и др. Применение бетаксолола у женщин с артериальной гипертонией в постменопаузе. Тер архив 1999; 6: 67-70.
19. Быстрова М.М., Бритов А.Н., Горбунов В.М. и др. Заместительная гормонотерапия у женщин с артериальной гипертонией в пери-и постменопаузе: гемодинамические эффекты. Тер архив 2001; 10: 33-8.
20. Глезер М.Г. Подтверждение безопасности и терапевтического эффекта бетаксолола при лечении легкой и умеренной артериальной гипертензии у женщин с климактерическим синдромом. Исследование SELena. Пробл жен здор 2008; 2:3-11.
21. Кириченко А.А., Танкиева З.М., Эбзеева Е.Ю. Эффективность и переносимость бетаксолола при лечении артериальной гипертензии у женщин в постменопаузе. Фарматека 2007; 20: 1-3.
22. Christ M, Rauen P, Klauss V, et al. Spontaneous changes of heart rate, blood pressure, and ischemia-type ST-segment depressions in patients with hypertension without significant coronary artery disease: beneficial effects of beta-blockade. J Cardiovasc Pharmacol 1996; 28(6): 755-63.
23. Моисеев В.С., Моисеев С.В. Бетаксолол (локрен) при артериальной гипертонии. Тер архив 1998; 2: 82-6.
24. Johnson BF, Whelton A. A Study Design for Comparing the Effects of Missing Daily Doses of Antihypertensive Drugs. Am J Ther 1994; 1(4): 260-7.
25. Ameling EH, de Korte DF, Man in ‘t Veld A. Impact of diagnosis and treatment of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of betaxolol. J Cardiovasc Pharmacol 1991; 18(5): 752-60.
26. Лазебник Л.Б., Комиссаренко И.А., Гусейнзаде М., Акурова М.Ю. Фармакодинамические эффекты локрена (бетаксо¬лола) при трехмесячном лечении артериальной гипертонии у пожилых. Тер архив 1998; 6: 44-7.
27. Kobayashi N, Nakano S, Mori Y, et al. Betaxolol Inhibits Extracellular Signal-Regulated Kinase and P70S6 Kinase Activities and Gene Expressions of Platelet-Derived Growth Factor A-Chain and Transforming Growth Factor-61 in Dahl Salt-Sensitive Hypertensive Rats. Hypertens Res 2002; 25:211-9.
28. De Gaudemaris R, Camaleonte A, Dimitriou R, et al. Interest of ambulatory blood pressure, exercise test recordings and echocardiographic measurements, in borderline arterial hypertension. Clin Exp Hypertens A 1985; 7(2-3): 371-9.
29. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-72.
30. 2007 Guidelines for the management of arterial hypertension.Eur Heart J 2007; 28: 1462-536.
31. Burris JF, Davidov ME, Jenkins P, et al. Comparison of the antihypertensive effects of betaxolol and chlorthalidone as monotherapy and in combination. Arch Intern Med 1989; 149(11): 2437-41.
32. Mann SJ, Gerber LM. Low-dose alpha/beta blockade in the treatment of essential hypertension. Am J Hypertens 2001; 14(6 Pt 1): 553-8.
33. Mann SJ, Gerber LM. Psychological characteristics and responses to antihypertensive drug therapy. J Clin Hypertens 2002; 4(1): 25-34.
34. Saku K, Zhang B, Okamoto T, et al. Medium-term effects of betaxolol monotherapy and combination therapy with nitrendipine on lipoprotein and apolipoprotein metabolism in patients with mild to moderate essential hypertension. J Hum Hypertens 1996; 10(4): 263-8.
35. Takase B, Takeishi Y, Hirai T, et al. Comparative effects of amlodipine monotherapy and combination therapy with betaxolol on cardiac autonomic nervous activity and health-related quality of life in patients with poorly controlled hypertension. Circ J 2008; 72(5): 764-9.
36. Takase B, Abe Y, Nagata M, et al. Effect of betaxolol hydrochloride on heart rate variability indices during exercise stress testing in patients with hypertension. Biomed Pharmacother 2005; 54. 59(Suppl 1): S158-62.
37. Дупляков Д.В., Глухова В.Л.,. Вождаева З.И, Головина ГА. Кардиоселективная бета-адреноблокада бетаксолом в лечении сердечно-сосудистых заболеваний. Тер архив 2006; 9: 43-8.
38. Irvine NA, Lipworth BJ, McDevitt DG. A dose-ranging study to evaluate the beta-adrenoceptor selectivity of single doses of betaxolol. Br J Clin Pharmacol 1990; 30(1): 119-26.
39. Uchida S, Itoh M, Fujimoto M, et al. Antihypertensive effects of betaxolol, a cardioselective beta-adrenoceptor antagonist, in stroke-prone spontaneously hypertensive rats (SHRSP). Nippon Yakurigaku Zasshi 1990; 96(2): 49-63.
40. Alpert MA, Mukerji V, Villarreal D, et al. Efficacy of betaxolol in the treatment of stable exertional angina pectoris: a dose-ranging study. Angiology 1990; 41(5): 365-76.
41. Chrysant SG, Bittar N. Betaxolol in the treatment of stable angina pectoris. Cardiology 1994; 84(4-5): 316-21.
42. Glasser SP, Friedman R, Talibi T, et al. Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris. Am J Cardiol 1994; 73(4): 213-8.
43. Narahara KA. Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Betaxolol Investigators Group. Am J Cardiol 1990; 65(9): 577-82.
44. Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. Vasc Health Risk Manag 2007; 3(2): 235-42.
45. Burger AJ, Kamalesh M, Kumar S, Nesto R. Effect of beta adrenergic receptor blockade on cardiac autonomic tone in patients with chronic stable angina. Pacing Clin Electrophysiol 1996; 19(4 Pt 1): 411-7.
46. Suzuki J, Watanabe K, Tsuruoka T, et al. Beneficial effects of betaxolol, a selective antagonist of beta-1 adrenoceptors, on exercise-induced myocardial ischemia in patients with coronary vasospasm. Int J Cardiol 2003; 91(2-3): 227-32.
47. Koh KK, Song JH, Kwon KS, et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Int J Cardiol 1995; 52(2): 167-74.
48. Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995; 75(1): 88-90.
49. Atwood JE, Myers J, Quaglieti S, et al. Effect of betaxolol on the hemodynamic, gas exchange, and cardiac output response to exercise in chronic atrial fibrillation. Chest 1999; 115: 1175-80.
50. Kuhlkamp V, Ickrath O, Haasis R, Seipel L. Electrophysiologic effects of betaxolol on conduction properties of the antegrade and retrograde pathway in patients with typical atrioventricular node reentry tachycardia following intravenous and oral administration. Z Kardiol 1988; 77(8): 527-33.
51. Kuhlkamp V, Ickrath O, Haasis R, Seipel L. Comparison of the effects of intravenous and oral betaxolol on antegrade and retrograde conduction in patients with atrioventricular nodal reentrant and atrioventricular reentrant tachycardia. Eur Heart J 1989; 10(6): 493-501.
52. Tonet J, Frank R, Fontaine G, Grosgogeat Y. Efficacy and safety of low doses of beta-blocker agents combined with amiodarone in refractory ventricular tachycardia. Pacing Clin Electrophysiol 1988; 11(11 Pt 2): 1984-9.
53. Watanabe K, Juan W, Narasimman G, et al. Betaxolol improves the survival rate and changes natriuretic peptide expression in rats with heart failure. J Cardiovasc Pharmacol 2003; 41(Suppl 1): S99-103.
54. Bohler S, Saubadu S, Scheldewaert R, Figulla HR. Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design. Arzneimittelforschung 1999; 49: 311-7.
55. Poole-Wilson PhA, Swedberg K, Cleland JGF, et al, for the COMET investigators Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
56. Figulla HR, Krzeminska-Pakula M, Wrabec K, et al. Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III Result of a randomized multicenter trial (BETACAR Trial). Intern J Cardiol 2006; 113: 153-60.
57. Morselli PL, Kilborn JR, Cavern L, et al. Betaxolol and other beta-adrenoreceptor antagonists. Raven Press 1983.
58. Benn JJ, Brown PM, Beckwith LJ, et al. Glucose turnover in type I diabetic subjects during exercise. Effect of selective and nonselective beta-blockade and insulin withdrawal. Diabetes Care 1992; 15(11): 1721-6.
59. Sinclair AJ, Davies IB, Warrington SJ. Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin. Br J Clin Pharmacol 1990; 30(5): 699-702.
60. Morselli PL, Boutroy MJ, Bianchetti G, et al. Placental transfer and perinatal pharmacokinetics of betaxolol. Eur J Clin Pharmacol 1990; 38: 477-83.
61. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and chemicals into human milk. Pediatrics 1994; 93: 137-50.
62. Beresford R, Heel RC. Betaxolol. Areview ofits pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension. Drugs 1986; 31(1): 6-28.
63. Patrick JM, Wharrad HJ, Wilson CG, Birmingham AT. The effect of a week’s beta-adrenoceptor antagonism on daytime heart-rates, subjective responses to exercise, and physical activity in normal subjects. Br J Clin Pharmacol 1985; 19(2): 177-85.
64. Grandordy BM, Thomas V, de Lauture D, Marsac J. Cumulative dose-response curves for assessing combined effects of salbutamol and ipratropium bromide in chronic asthma. Eur Respir J 1988; 1(6): 531-5.
Review
For citations:
Duplyakov D.V. Cardioselective beta-adrenoreceptor blockade with betaxolol in cardiovascular therapy. Cardiovascular Therapy and Prevention. 2009;8(4):103-112. (In Russ.)
Views:
769
Email this article 
